

CARDIOVASCULAR SYSTEMS INC
Form 3
December 29, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Borrell John R		(Month/Day/Year)	CARDIOVASCULAR SYSTEMS INC [CSII]	
(Last)	(First)	(Middle)	12/29/2008	
651 CAMPUS DRIVE			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
ST. PAUL,Â MNÂ 55112			<input type="checkbox"/> Director	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			(specify below)	
			VP of Sales / Mbr of 13(d) grp	
			owng > 10%	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	23,000	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: CARDIOVASCULAR SYSTEMS INC - Form 3

				Shares		(I) (Instr. 5)	
Series A-1 Conv Preferred Stock	Â (1)	Â (1)	Common Stock	12,135	\$ (1)	D	Â
Stock Option (right to buy)	Â (2)	06/30/2011	Common Stock	132,000	\$ 5.71	D	Â
Stock Option (right to buy)	Â (3)	12/18/2016	Common Stock	8,000	\$ 5.71	D	Â
Stock Option (right to buy)	Â (4)	04/17/2017	Common Stock	34,000	\$ 5.71	D	Â
Stock Option (right to buy)	Â (5)	08/06/2017	Common Stock	35,000	\$ 5.11	D	Â
Stock Option (right to buy)	Â (6)	12/11/2017	Common Stock	100,000	\$ 7.86	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Borrell John R 651 CAMPUS DRIVE ST. PAUL, MN 55112	Â	Â	Â VP of Sales	Mbr of 13(d) grp owng > 10%

Signatures

/s/ Carlye S. Landin as Attorney-in-Fact for John R. Borrell pursuant to Power of Attorney filed herewith.

12/29/2008

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of Series A-1 convertible preferred stock is convertible at any time, at the holder's election, into 1.03 shares of common stock and has no expiration date.
- (2) Exercisable in three equal increments of 44,000 on 7/1/07, 7/1/08 and 7/1/09.
- (3) Exercisable: 2,667 on 12/19/07 and 12/19/08 and 2,666 on 12/19/09.
- (4) Exercisable: 11,333 on 4/18/08 and 4/18/09 and 11,334 on 4/18/10.
- (5) Exercisable: 11,667 on 8/7/08 and 8/7/09 and 11,666 on 8/7/10.
- (6) Exercisable: 50,000 on the first anniversary of the closing of the Company's merger with Replidyne, Inc. and 50,000 on the second anniversary of the merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.